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Abstract
Three suitable compounds (morphine, chlorpromazine, and phenobarbital) to treat neonatal abstinence syndrome were compared
in a prospective multicenter, double-blind trial. Neonates exposed to opioids in utero were randomly allocated to one of three
treatment groups. When a predefined threshold of a modified Finnegan score was reached, treatment started and increased
stepwise until symptoms were controlled. If symptoms could not be controlled with the predefined maximal dose of a single
drug, a second drugwas added. Among 143 infants recruited, 120 needed pharmacological treatment.Median length of treatment
for morphine was 22 days (95%CI 18 to 33), for chlorpromazine 25 days (95%CI 21 to 34), and for phenobarbital 32 days (95%
CI 27 to 38) (p = ns). In the morphine group, only 3% of infants (1/33) needed a second drug; in the chlorpromazine group, this
proportion was 56% (24/43), and in the phenobarbital group 30% (13/44).
Conclusion: None of the drugs tested for treating neonatal abstinence syndrome resulted in a significantly shorter treatment
length than the others. As morphine alone was able to control symptoms in almost all infants, it may be preferred to the two other
drugs but should still be tested against more potent opioids such as buprenorphine.
Trial registration: At ClinicalTrials.gov NCT02810782 (registered retrospectively).
What is Known:
• Neonates exposed to opiates in utero and presenting with withdrawal symptoms should first be treated by non-pharmacological supportive measures.
• In those who fail, drugs have to be given, but there is controversy which drug is best.
What is New:
• Among three candidates, morphine, chlorpromazine and phenobarbital, none resulted in significantly shorter treatment time.
• As morphine alone was able to control symptoms in almost all infants, it may be preferred to the two other drugs.
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Introduction
The incidence of withdrawal symptoms in newborns exposed
to opioids during pregnancy, termed neonatal abstinence syn-
drome, has increased in the last 20 years and has reached
epidemic proportions in high-income countries (2–6/1000 live
births) [2]. Neonatal abstinence syndrome not only poses an
important burden of suffering on infants and families but also
contributes to the occupancy of neonatal beds and generates
considerable health care costs [5].
There is consensus that management of neonatal abstinence
syndrome should primarily be focused on reducing symptoms
of withdrawal such as hyperirritability, excessive crying, poor
feeding, vomiting, and diarrhea [12]. In the first instance, non-
pharmacological supportive measures are indicated, such as
quiet environment and frequent feeds to ensure sufficient ca-
loric intake [10]. However, in up to 60% of infants with neo-
natal abstinence syndrome, pharmacological therapy has to be
given to control persistent neurological and gastrointestinal
symptoms [13].
The present study was designed in the late 1990s as part of
a national program addressing detoxification supported by the
Swiss Health Agency. At that time, several substances were
used to treat neonatal abstinence syndrome, but few random-
ized controlled studies were available, and there was no con-
sensus about the best medication or the optimal dose [8].
Morphine and phenobarbital were most widely used in the
USA [21]. Chlorpromazine was most commonly used in the
UK for its effect on the central nervous system and the gas-
trointestinal system [17]. Phenobarbital was mainly used with
loading and maintenance doses for its sedative and anticon-
vulsant properties [19].
The goal of the trial reported here was to compare three
substances in a double-blind multicenter trial for the treatment
of neonatal abstinence syndrome.
Methods
This was a multicenter, double-blind, parallel-group study
with three arms conducted in seven neonatal intensive care
units in Switzerland.
The main objective was to document the effect of three
drugs (oral morphine solution, chlorpromazine, phenobarbi-
tal) on the length of treatment based on the modified Finnegan
score. Secondary objectives were to document the need for a
second drug, the occurrence of seizures, and other adverse
events. We included late preterm and term infants (34 gesta-
tional weeks or more) who had withdrawal symptoms and
were born to mothers who took opioids, including methadone,
during pregnancy.We excluded infants with diseases probably
requiring a long hospitalization.
All infants with reported maternal opioid consumption and
suspected neonatal abstinence syndrome were assessed with a
modified Finnegan score every 8 h, the standard interval in
Swiss Hospitals [23]. If an infant scored once above 14 or
twice in a row above 9, and the parents had given written
consent, the infant was randomized to group A (morphine),
B (chlorpromazine), or C (phenobarbital).
The following possible confounders for the primary out-
come were collected: hospital, gestational age at birth, birth
weight, head circumference at birth, sex, pH in umbilical ar-
tery, mode of delivery, Apgar score at 5 min of life, postnatal
intervention, socioeconomic status of the parents (scale 2–12,
2 = highest status [14]), and drugs detected in the meconium.
Preparation and administration of study drug (Fig. 1)
Vials with the study drug were prepared in the pharmacy of
Zurich University Hospital according to a computer-generated
randomization list, labelled, shipped, and stored according to
the Swiss Therapeutic Product Act of 15 December 2000. In
order to mask group allocation, water, ethanol, glycerine, and
caramel color (E150) were added to the active substance, and
dosing regime was standardized. Since phenobarbital treat-
ment needs a loading dose and morphine and chlorpromazine
do not, each of the three substances was prepared in two dis-
tinctive vials. A red-labelled vial contained the solution to be
given as a starting dose: 0.25 ml of the solution contained
either 0.25 mg morphine or 0.5 mg chlorpromazine or
10 mg phenobarbital. White-labelled vials with the standard
solution of morphine and chlorpromazine were identical to the
starting solution, while the standard solution of phenobarbital
contained 0.83 mg/0.25 ml. If pharmacological treatment was
indicated, the infant first received a dose of 0.25 ml per kilo-
gram body weight of the starting solution (red-labelled vial),
followed by 0.25 ml per kilogram body weight of the white-
labelled standard solution every 4 h. The drugs were given
orally or by nasogastric tube. Physicians, nurses, and parents
were blinded.
Increase of dose
After initiation of therapy (see above), a modified
Finnegan score was recorded every 8 h [23]. Each time
the score was above 9, the study drug was increased by
0.05 ml/kg until a maximum dose of 0.5 ml/kg was
achieved or the withdrawal symptoms were controlled.
The symptoms were judged to be controlled if the modi-
fied Finnegan score was below 9 on three consecutive
measurements. If symptoms were not controlled by the
defined maximum dose of the allocated drug, a second
drug was added following the same algorithm as the first
drug. The first drug was continued at the maximal level.
The predefined maximum doses of the drugs led to daily
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dosages of 3 mg/kg for morphine, 3 mg/kg for chlorprom-
azine, and 10 mg/kg for phenobarbital. The second drug
was predefined by allocation of the first drug and also
blinded. If the first drug was morphine, the second drug
was phenobarbital. If the first drug was phenobarbital or
chlorpromazine, the second drug was morphine.
Reduction of dose
If symptoms were controlled, the allocated drug or the com-
bination of two drugs was administered at the same dose for
the next 72 h. After this stabilization period, the drugs were
reduced stepwise. If the mean modified Finnegan score for the
Fig. 1 Therapy algorithm. Medications are started, increased, decreased, or stopped depending on a modified Finnegan score. If symptoms were not
controlled by the predefined maximal dose of the first allocated drug, a second drug was added following the same algorithm as the first drug
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last 24 h was below 8, the drug was reduced by 10%. If the
mean score was 8 or 9, the drug dose was kept unchanged, and
if the mean score was above 9, the drug was increased again to
the previous level. If two drugs had to be given, the first drug
was reduced first. If the infant needed no more drugs for 2
days, it could be discharged.
Monitoring
The infants were routinely assessed clinically: modified
Finnegan score every 8 h, clinical examination and weight
daily. Two samples of meconium were analyzed for opioids,
methadone, amphetamine, barbiturate, benzodiazepine, co-
caine, and cannabis. Blood glucose and electrolytes were in-
vestigated only on clinical indication.
Suffering was quantified with the sum of modified
Finnegan scores above 9 for the whole treatment period.
Intensity of care was documented continuously based on
how much time nurses spent with one infant, documented in
intervals of 15 min during 24 h.
Sample size calculation
The primary objective of this study was the length of pharma-
cological treatment. A retrospective analysis of 90 neonates
born to opioid-addicted mothers in the University Hospital
Zurich over a period of 10 years found that the mean length
of treatment of infants with neonatal abstinence syndromewas
30 days with a SD of ± 12 days. We considered a difference of
more than 1 week (8 days or more) to be clinically and eco-
nomically important. To detect a difference of 8 days between
two groups, we calculated a minimal sample size of 36 (alpha
0.05, power 80%) per group.
Statistical methods
The treatment time and hospitalization time were analyzed
using a Kaplan-Meier time-to-event analysis. The resulting
curves were then compared using the Peto modification of
the log-rank test. To adjust for covariates, a Cox proportional
hazard regression and Weibull models were used, the latter
allowing for the computation of event–time ratios [4]. The
need for a second drug was analyzed using logistic regression
and Fisher’s exact test.
The global p value for an effect of treatment between the
model with and without the treatment term was assessed with
a likelihood ratio test (LR). Suffering, defined as the sum of
modified Finnegan scores > 9, was analyzed using a linear
model with the scores as the dependent variables, which were
log10 transformed to guarantee normality and a constant var-
iance of the residuals. Similarly, a linear model was used to
analyze the intensity of care.
The association of the drugs found in the meconium with
treatment length was tested using univariable linear models
and a multivariable linear model.
The study protocol was approved by the Ethics Review
Board of the Canton Zurich and by the Swiss Agency for
Therapeutic Products (StV Nr. 11/00). All parents gave writ-
ten informed consent to participate in the study.
Results
A total of 204 infants born to a mother who reported taking
opioids, including methadone, during pregnancy were
assessed for eligibility in the seven participating hospitals
(see flow diagram in Fig. 2). Of these, 61 infants were exclud-
ed for not meeting all inclusion criteria, of whom 15 were
because parents refused consent.
Among the 43 infants allocated to intervention A (mor-
phine), 10 did not reach the criteria for treatment during the
whole observation period and therefore did not receive the
allocated drug. In intervention B (chlorpromazine), 9 out of
53 infants and in intervention C (phenobarbital), 4 out of 47
infants did not need treatment and consequently were not in-
cluded in the analysis.
The three study groups were well balanced, and there was
no difference in sex, gestational age, birth weight, head cir-
cumference, mode of delivery, Apgar score at 5 min, pH in
umbilical artery, need for postnatal intervention or socioeco-
nomic status of the parents (Table 1).
There was no significant difference in length of medical
treatment among groups. Median length of medical treatment
in the morphine group was 22 days (95%CI from 18 to 33), in
the chlorpromazine group 25 days (95% CI from 21 to 34),
and in the phenobarbital group 32 (95% CI from 27 to 38 )
days (p = 0.12, Kaplan-Meier Curves in Fig. 3).
In the statistical analysis adjusted for sex, gestational age,
small for gestational age (birth weight < 10th percentile), so-
cioeconomic status, polydrug use of mother, and center, the
chlorpromazine group had 17% longer treatment time (ETR
1.17, p = 0.15) and the phenobarbital group 16% longer treat-
ment time than the morphine group (ETR 1.16, p = 0.19);
neither difference was statistically significant.
Hospitalization time in the adjusted analysis was 5% longer
in the chlorpromazine group than in the morphine group (ETR
1.05, p = 0.61) and 13% longer in the phenobarbital group
than in the morphine group (ETR 1.13, p = 0.21). Neither
difference reached statistical significance.
The need for a second medication differed considerably
between the three groups. In the morphine group, only one
out of 33 infants (3%) needed a second drug, but in the chlor-
promazine group, the equivalent figure was 24 out of 44
(55%), and in the phenobarbital group, 13 infants out of 43
(30%) (Fisher’s exact test, p < 0.0001).
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The majority of the mothers (71%) were multi-drug users.
The meconium analyses detected amphetamine (n = 33
[27.5%]), barbiturate (n = 19 [15.8%]), benzodiazepine (n =
22 [18.3%]), cannabis (n = 27 [22.5%]), and cocaine (n = 28
[23.3%]) (Table 2).
Among the cofactors correlating with the primary outcome,
only amphetamine in the meconium analysis was associated
with a significantly shorter length of treatment (minus 7.6
days, p < 0.03, Table 3).
The mean suffering score (sum of modified Finnegan
scores > 9) was 238 (SD 180) for the morphine group, 277
(SD 152) for the chlorpromazine group, and 313 (SD 300) for
the phenobarbital group. The analysis with adjusted and un-
adjusted models showed no treatment effect. In the 22 infants
who did not need treatment, the mean suffering score was 14
(SD 28).
Intensity of care (nursing time) was 7 h per 24 h and did not
differ significantly between the three groups in either the ad-
justed or the unadjusted model.
No seizures except tremor and sleep myoclonus,
known to be associated with opioid withdrawal [9],
were reported. Twelve infants (36%) in the morphine
group, 13 infants (30%) in the chlorpromazine group,
and 16 infants (36%) in the phenobarbital group showed
at least one episode of hypothermia (rectal temperature
below 36.0 °C or axillary temperature below 35.5°). No
adverse events were observed that were not attributable
to withdrawal.
Assessed for eligibility (n=204)
Excluded  (n=61)
Not meeting inclusion criteria (n=46 )
Declined to participate (n=15 )
Analysed  (n=33)
Excluded from analysis  (n=0)
Needed second drug (n=1)
Lost to follow-up (n=0)
Allocated to intervention A
(Morphine, n=43)
Received allocated 
intervention (n=33)
Did not need allocated 
intervention* (n=10)
Allocation
Follow-Up
Randomized (n=143)
Enrollment
Allocated to intervention B
(Phenobarbital, n=53)
Received allocated 
intervention (n=44)
Did not need allocated 
intervention* (n=9)
Allocated to intervention C
(Chlorpromazine, n=47)
Received allocated 
intervention (n=43)
Did not need allocated 
intervention* (n=4)
Needed second drug (n=24)
Lost to follow-up (n=0)
Needed second drug (n=13)
Lost to follow-up (n=0)
Analysed  (n=44)
Excluded from analysis (n=0)
Analysed  (n=43)
Excluded from analysis (n=0)
Analysis
Ref. CONSORT 2010*did not reach high Finnegan scores
Fig. 2 Flow diagram (reference CONSORT 2010)
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Table 1 Group characteristics
Morphine
(n = 43)
Chlorpromazine
(n = 53)
Phenobarbital
(n = 47)
p Test
Sex
Female 19 44.2% 25 47.2% 23 48.9% 0.902 Chi-square
Male 24 55.8% 28 52.8% 24 51.1%
Gestational age
(weeks, median [IQR])
38.14 [37.0, 38.93] 38.36 [37.14, 38.0] 39.0 [38.0, 40.0] 0.073 ANOVA
37 (0/7)–42 (0/7) 34 79.1% 43 82.7% 44 93.6%
34 (0/7)–36 (6/7) 9 20.9% 9 17.3% 3 6.4%
Birth weight
(g, median [IQR])
2700 [2452, 3070] 2765 [2443, 3100] 2800 [2540, 3070] 0.646 ANOVA
Small for GA
(< 10th percentile)
18 41.9% 20 37.7% 19 40.4%
Head circumference
(cm, median [IQR])
33.0 [32.0, 34.5] 33.0 [32.0, 34.0] 33.0 [32.0, 33.5] 0.765 ANOVA
Microcephaly
(< 10th percentile)
11 25.6% 19 35.8% 13 27.7%
Mode of delivery 0.32 Chi-square
Spontaneous 16 37.2% 28 53.8% 27 57.4%
Cesarean section 21 48.8% 17 32.7% 16 34.0%
Vacuum or forceps 6 14.0% 7 13.5% 4 8.5%
Apgar 5 min (median
[IQR])
9 [9, 9] 9 [9, 9] 9 [9, 9] 0.829 Kruskal
< 6 0 0.0% 1 2.1% 1 2.4%
pH in umbilical artery
(median, [IQR])
7.27 [7.22, 7.33] 7.28 [7.23, 7.3] 7.25 [7.21, 7.29] 0.353 ANOVA
NA-pH < 7.15 1 2.4% 3 6.5% 2 4.8%
Postnatal intervention
(bag and mask or
supplemental oxygen)
3 7.0% 2 3.8% 2 4.3% 0.746 Chi-square
Socioeconomic status
of parents (median
[IQR])
8 [7, 9] 7 [6, 8] 7 [6, 8] 0.718 Kruskal
Fig. 3 Kaplan-Meier and log
cumulative hazard curves for
treatment length and for
hospitalization length. p values of
a log-rank test are added. The
time-to-event curves in the
Kaplan-Meier plots can be
interpreted as the complementary
empirical distribution functions
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Discussion
The main finding of this trial is that none of the three drugs for
controlling withdrawal symptoms in newborns to mothers who
consumed opioids during pregnancy shortened treatment length
compared with the other two. However, only one infant (3%)
allocated to the treatment with morphine needed a second drug,
whereas 55% of infants treated with chlorpromazine and 30%
of infants treated with phenobarbital needed a second drug.
A systematic search in PubMed and Scopus found only a
few controlled studies to compare with our results. Jackson
et al. reported a shorter treatment length with morphine (n =
41, mean 8 days) than with phenobarbital (n = 34, mean 12
days, p = 0.04) [11], whereas Nayeri et al. found no significant
difference in duration of treatment, duration of hospital stay, or
requirement for adjunctive treatment between neonates with
neonatal abstinence syndrome who received morphine sulfate
and neonates who received a loading and tapering dose of
phenobarbital [18]. A Cochrane review concluded that pheno-
barbital not only has a longer treatment length than morphine
but is also associated with a higher incidence of seizures [20].
Therefore, it should no longer be used as a first-line drug [22].
The only trial comparing chlorpromazine with morphine
used a historical control. Mazurier et al. found a mean length
of 6 (range 3.5–9) days in infants treated with morphine, com-
pared with 16 (10–21) days in infants treated with chlorprom-
azine (p < 0.001) [16]. Since this trial was published, safety
concerns have been raised about chlorpromazine in infants
younger than 6 months of age, and it therefore should no longer
be used to treat neonatal abstinence syndrome.
In a recentmeta-analysis including 18 trials, buprenorphine, a
more potent analgesic than morphine, was suggested as the op-
timal treatment for neonatal abstinence syndrome. However, it
concluded that limitations were considerable, and a large multi-
site trial of this treatment is required [6].
Another unresolved issue is dosing.Opioid pharmacokinetics
vary considerably between infants [3]. Morphine has a short
half-life and therefore has to be administered frequently, usually
every 4 h. For blinding, the dose interval had to be the same for
all three substances, even though this was not necessary for
phenobarbital or chlorpromazine, as both have a longer half-life.
Consequently, we started dosing with a relatively high dose of
0.25 mg per kilogram body weight, increasing stepwise up to
0.5 mg/kg (Fig. 1). The high initial dose was based on clinical
experience that infants exposed in utero to an unknown quantity
of opioids were better controlled with initial high dose and
down-titration than a low initial dose and up-titration.
However, this strategy did not allow us to observe respiratory
insufficiency or other adverse effects. Down-titration could be
started immediately after the first maintenance dose in two in-
fants. Only one infant reached the predefined maximal dose of
0.5 mg/kg and therefore received a second drug.
We quantified suffering during withdrawal by calculating
the area under the curve defined by the sum of modified
Finnegan scores above 9 for each 8-h monitoring period.
The time spent with a modified Finnegan score above 9 is a
valid measure for suffering, since it has been shown that
healthy newborns without neonatal abstinence syndrome
may present symptoms contributing to an elevated modified
Finnegan score, but the 95th percentile never exceeds 8 [23].
This suffering score was similar for all three groups.
We also estimated the need for staff resources by calculating
the time that nurses spent with one infant. This was between 7
and 8 h per 24 h for all three groups, which is more than the
mean nursing time (6 h per 24 h) in an intermediate care unit.
No adverse events other than those monitored by the
Finnegan score were observed in our study, including seizures
other than benign sleep myoclonus; this is known to be
Table 2 Results of meconium analyses in the tree groups
Morphine (n = 33) Phenobarbital (n = 44) Chlorpromazine (n = 43) Total
n % n % n % n %
Amphetamine 12 36.4% 11 25.0% 10 23.3% 33 27.5%
Barbiturate 4 12.1% 8 18.2% 7 16.3% 19 15.8%
Benzodiazepine 7 21.2% 6 13.6% 9 20.9% 22 18.3%
Cannabis 4 12.1% 6 13.6% 17 39.5% 27 22.5%
Cocaine 7 21.2% 10 22.7% 11 25.6% 28 23.3%
Methadone 28 84.8% 43 97.7% 35 81.4% 106 88.3%
Opioid 17 51.5% 25 56.8% 32 74.4% 74 61.7%
Table 3 Effect of drugs found in the meconium on treatment time in
days
Univariable Multivariable
Amphetamine − 6.63 p = 0.04 − 7.652 p = 0.03
Barbiturate − 2.03 p = 0.6 0.842 p = 0.84
Benzodiazepine − 3.26 p = 0.37 − 3.145 p = 0.35
Cannabis − 3.24 p = 0.34 − 1.476 p = 0.68
Cocaine 1.19 p = 0.72 4.442 p = 0.21
Linear model with univariable and multivariable analyses
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associated with both, morphine (12) and withdrawal itself.
Episodes of hypothermia, known as a side effect of chlor-
promazine, were documented in all three groups to the same
extent and quickly resolved after warming the infant.
Among the potential confounders for length of treatment, only
amphetamine in the meconium was positively correlated
(Table 3). We did not expect this finding and could not find a
similar observation in the literature. As amphetamine increases
dopamine release and is sympathomimetic, we speculate that they
may shorten neonatal abstinence syndrome. The exact mecha-
nism needs to be elucidated. We would not recommend giving
amphetamines to pregnant women consuming opioids in order to
shorten neonatal abstinence syndrome, since the short-term and
long-term adverse effects of prenatal amphetamine exposure are
well documented in both, animal studies and human observation-
al studies, including behavior problems at school age [7].
Strengths of this study are the consistent blinding of all
health professionals, parents, and statisticians involved in the
trial and the adherence to a strict treatment protocol, including
tapering medication. It is a rare example of a well-designed
and well-performed clinical trial in the vulnerable population
of newborns [1, 15].
A weakness of the study is that infants were randomized
before they reached a high modified Finnegan score for logis-
tical reasons, so some did not need pharmacological treatment
and were analyzed separately. The fact that neither opioid
exposure nor exposure to other drugs during pregnancy could
be quantified is also a potential problem, since the degree of
drug exposure in utero may affect weaning symptoms.
Finally, this study was performed between the years 2001
and 2007, when drugs such as chlorpromazine and phenobar-
bital were used as first choice for neonatal abstinence syn-
drome whereas morphine was avoided to limit exposure after
birth. Due to the expiry of funds and the promotion of the
principal investigator to another position, data were not ana-
lyzed promptly. When reviewing the data in 2017, we con-
cluded that publication of these data would still be of value,
mainly because blinded, randomized data on neonatal absti-
nence syndrome treatment is sparse.
Summary and conclusions
None of the tested drugs to treat neonatal abstinence syndrome
resulted in a significantly shorter treatment length than the
others. As morphine was able to control symptoms in almost
all infants without adjuvant therapy, it may be preferred to the
two other compounds but has to be tested against more potent
opioids such as buprenorphine.
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